Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Modulation of cellular radiation responses by histone deacetylase inhibitors

Oncogene volume 25, pages 3885–3893 (2006)Cite this article

Abstract

Histone deacetylase (HDAC) inhibitors are emerging as a new class of targeted cancer chemotherapeutics. Several HDAC inhibitors are currently in clinical trials and promising anticancer effects at well-tolerated doses have been observed for both hematologic and solid cancers. HDAC inhibitors have been shown to induce cell-cycle and growth arrest, differentiation and in certain cases apoptosis in cell cultures and in vivo. However, it is known that these compounds induce varying responses in different cells and biological settings, and identifying their precise mechanisms of action is an area of great interest. Important findings are continually expanding our understanding of the cellular effects of HDAC inhibitors and recent studies will be briefly outlined in this review. In addition to their intrinsic anticancer properties, numerous studies have demonstrated that HDAC inhibitors can modulate cellular responses to other cytotoxic modalities including ionizing radiation, ultraviolet radiation and chemotherapeutic drugs. Hence, there is a growing interest in potential clinical use of HDAC inhibitors in combination with conventional cancer therapies. In this review, the interaction of HDAC inhibitors with other anticancer agents is discussed. The focus of the article is on the different mechanisms by which HDAC inhibitors enhance the sensitivity of cells to the effects of ionizing radiation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Abraham RT . (2001). Genes Dev 15: 2177–2196.

  • Alland L, Muhle R, Hou Jr H, Potes J, Chin L, Schreiber-Agus N et al. (1997). Nature 387: 49–55.

  • Arundel CM, Glicksman AS, Leith JT . (1985). Radiat Res 104: 443–448.

  • Arundel CM, Leith JT . (1987). Int J Radiat Oncol Biol Phys 13: 593–601.

  • Biade S, Stobbe CC, Boyd JT, Chapman JD . (2001). Int J Radiat Biol 77: 1033–1042.

  • Blaheta RA, Michaelis M, Driever PH, Cinatl Jr J . (2005). Med Res Rev 25: 383–397.

  • Boivin AJ, Momparler LF, Hurtubise A, Momparler RL . (2002). Anticancer Drugs 13: 869–874.

  • Bowden CL, Singh V . (2005). Acta Psychiatr Scand Suppl 426: 13–20.

  • Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY et al. (1996). Cell 84: 843–851.

  • Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA et al. (2002). Proc Natl Acad Sci USA 99: 11700–11705.

  • Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ et al. (2004a). Cancer Res 64: 316–321.

  • Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA et al. (2005). Int J Cancer 114: 380–386.

  • Camphausen K, Scott T, Sproull M, Tofilon PJ . (2004b). Clin Cancer Res 10: 6066–6071.

  • Celeste A, Fernandez-Capetillo O, Kruhlak MJ, Pilch DR, Staudt DW, Lee A et al. (2003). Nat Cell Biol 5: 675–679.

  • Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS et al. (1999). J Clin Oncol 17: 984–990.

  • Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM . (2005). Int J Radiat Oncol Biol Phys 62: 223–229.

  • Chiu CY, Cary RB, Chen DJ, Peterson SR, Stewart PL . (1998). J Mol Biol 284: 1075–1081.

  • Chung YL, Lee YH, Yen SH, Chi KH . (2000). Clin Cancer Res 6: 1452–1458.

  • Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL et al. (1998). EMBO J 17: 159–169.

  • de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB . (2003). Biochem J 370: 737–749.

  • de Vries E, van Driel W, Bergsma WG, Arnberg AC, van der Vliet PC . (1989). J Mol Biol 208: 65–78.

  • Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A . (2004). Amino Acids 26: 435–441.

  • Dokmanovic M, Marks PA . (2005). J Cell Biochem 96: 293–304.

  • Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC . (2005). Annu Rev Pharmacol Toxicol 45: 495–528.

  • Durocher D, Jackson SP . (2001). Curr Opin Cell Biol 13: 225–231.

  • Falzon M, Fewell JW, Kuff EL . (1993). J Biol Chem 268: 10546–10552.

  • Ferguson DO, Alt FW . (2001). Oncogene 20: 5572–5579.

  • Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA et al. (1999). Nature 401: 188–193.

  • Fischle W, Wang Y, Allis CD . (2003). Nature 425: 475–479.

  • Frey RR, Wada CK, Garland RB, Curtin ML, Michaelides MR, Li J et al. (2002). Bioorg Med Chem Lett 12: 3443–3447.

  • Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S . (2001). Proc Natl Acad Sci USA 98: 87–92.

  • Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H et al. (2002). Cancer Res 62: 4916–4921.

  • Gregoretti IV, Lee YM, Goodson HV . (2004). J Mol Biol 338: 17–31.

  • Gregory PD, Wagner K, Horz W . (2001). Exp Cell Res 265: 195–202.

  • Grozinger CM, Schreiber SL . (2002). Chem Biol 9: 3–16.

  • Grunstein M . (1997). Nature 389: 349–352.

  • Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS . (2004). Cancer Res 64: 1079–1086.

  • Hammarsten O, Chu G . (1998). Proc Natl Acad Sci USA 95: 525–530.

  • Hess-Stumpp H . (2005). Eur J Cell Biol 84: 109–121.

  • Jackson SP . (2001). Biochem Soc Trans 29: 655–661.

  • Jackson SP . (2002). Carcinogenesis 23: 687–696.

  • Jeggo P, O'Neill P . (2002). DNA Repair (Amsterdam) 1: 771–777.

  • Jenuwein T, Allis CD . (2001). Science 293: 1074–1080.

  • Johnstone RW . (2002). Nat Rev Drug Discov 1: 287–299.

  • Johnstone RW, Licht JD . (2003). Cancer Cell 4: 13–18.

  • Ju R, Muller MT . (2003). Cancer Res 63: 2891–2897.

  • Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS et al. (2000). J Biol Chem 275: 20436–20443.

  • Jung M . (2001). Curr Med Chem 8: 1505–1511.

  • Jung M, Velena A, Chen B, Petukhov PA, Kozikowski AP, Dritschilo A . (2005). Radiat Res 163: 488–493.

  • Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ . (2003). J Cell Biol 160: 1017–1027.

  • Karagiannis TC, Kn H, El-Osta A . (2005). Cancer Biol Ther 4: 787–793.

  • Kastan MB, Lim DS, Kim ST, Xu B, Canman C . (2000). Cold Spring Harb Symp Quant Biol 65: 521–526.

  • Kelly WK, Marks PA . (2005). Nat Clin Pract Oncol 2: 150–157.

  • Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T et al. (2005). J Clin Oncol 23: 3923–3931.

  • Kelly WK, O'Connor OA, Marks PA . (2002). Expert Opin Investig Drugs 11: 1695–1713.

  • Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W et al. (2003). Clin Cancer Res 9: 3578–3588.

  • Khanna KK . (2000). J Natl Cancer Inst 92: 795–802.

  • Khanna KK, Jackson SP . (2001). Nat Genet 27: 247–254.

  • Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D . (2001). Curr Opin Genet Dev 11: 162–166.

  • Kim GD, Choi YH, Dimtchev A, Jeong SJ, Dritschilo A, Jung M . (1999). J Biol Chem 274: 31127–31130.

  • Kim JH, Shin JH, Kim IH . (2004). Int J Radiat Oncol Biol Phys 59: 1174–1180.

  • Kim MS, Baek JH, Chakravarty D, Sidransky D, Carrier F . (2005). Exp Cell Res 306: 94–102.

  • Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F . (2003). Cancer Res 63: 7291–7300.

  • Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al. (2001). Nat Med 7: 437–443.

  • Kim ST, Lim DS, Canman CE, Kastan MB . (1999). J Biol Chem 274: 37538–37543.

  • Kouzarides T . (1999). Curr Opin Genet Dev 9: 40–48.

  • Kouzarides T . (2000). EMBO J 19: 1176–1179.

  • Kruh J . (1982). Mol Cell Biochem 42: 65–82.

  • Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G et al. (2002). EMBO J 21: 2672–2681.

  • Lee SE, Moore JK, Holmes A, Umezu K, Kolodner RD, Haber JE . (1998). Cell 94: 399–409.

  • Leith JT . (1988). Radiat Res 114: 186–191.

  • Lieber MR, Ma Y, Pannicke U, Schwarz K . (2003). Nat Rev Mol Cell Biol 4: 712–720.

  • Loscher W . (1999). Prog Neurobiol 58: 31–59.

  • Louis M, Rosato RR, Battaglia E, Neguesque A, Lapotre A, Grant S et al. (2005). Int J Oncol 26: 1569–1574.

  • Luo J, Su F, Chen D, Shiloh A, Gu W . (2000). Nature 408: 377–381.

  • Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK . (2001). Nat Rev Cancer 1: 194–202.

  • Marks PA, Jiang X . (2005). Cell Cycle 4: 549–551.

  • Marks PA, Richon VM, Miller T, Kelly WK . (2004). Adv Cancer Res 91: 137–168.

  • Marks PA, Richon VM, Rifkind RA . (2000). J Natl Cancer Inst 92: 1210–1216.

  • Miller AA, Kurschel E, Osieka R, Schmidt CG . (1987). Eur J Cancer Clin Oncol 23: 1283–1287.

  • Mimori T, Hardin JA . (1986). J Biol Chem 261: 10375–10379.

  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al. (2004). Proc Natl Acad Sci USA 101: 540–545.

  • Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL et al. (2005). Clin Cancer Res 11: 4912–4922.

  • Nakano K, Vousden KH . (2001). Mol Cell 7: 683–694.

  • Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH . (2005). Mol Cancer Ther 4: 1231–1238.

  • Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. (2000). Science 288: 1053–1058.

  • Olive PL, Banath JP . (2004). Int J Radiat Oncol Biol Phys 58: 331–335.

  • Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM . (2000). Curr Biol 10: 886–895.

  • Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE et al. (1993). N Engl J Med 328: 81–86.

  • Perucca E . (2002). CNS Drugs 16: 695–714.

  • Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M et al. (1995). Nature 376: 348–351.

  • Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS . (2001). J Biol Chem 276: 36734–36741.

  • Piekarz R, Bates S . (2004). Curr Pharm Des 10: 2289–2298.

  • Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH et al. (2004). Blood 103: 4636–4643.

  • Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L et al. (2001). Invest New Drugs 19: 1–11.

  • Rich T, Allen RL, Wyllie AH . (2000). Nature 407: 777–783.

  • Richardson C, Jasin M . (2000). Nature 405: 697–700.

  • Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al. (1998). Proc Natl Acad Sci USA 95: 3003–3007.

  • Rogakou EP, Boon C, Redon C, Bonner WM . (1999). J Cell Biol 146: 905–916.

  • Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM . (1998). J Biol Chem 273: 5858–5868.

  • Rooney S, Alt FW, Lombard D, Whitlow S, Eckersdorff M, Fleming J et al. (2003). J Exp Med 197: 553–565.

  • Rotman G, Shiloh Y . (1999). Oncogene 18: 6135–6144.

  • Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T et al. (1999). Proc Natl Acad Sci USA 96: 4592–4597.

  • Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A et al. (1998). Genes Dev 12: 2831–2841.

  • Singh SB, Zink DL, Liesch JM, Mosley RT, Dombrowski AW, Bills GF et al. (2002). J Org Chem 67: 815–825.

  • Snead III OC, Miles MV . (1985). J Pediatr 106: 323–325.

  • Spotswood HT, Turner BM . (2002). J Clin Invest 110: 577–582.

  • Struhl K . (1998). Genes Dev 12: 599–606.

  • Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L et al. (2005). Blood [ DOI 10.1182/blood-2004-10-4126].

  • Taddei A, Roche D, Bickmore WA, Almouzni G . (2005). EMBO Rep 6: 520–524.

  • Teo SH, Jackson SP . (1997). EMBO J 16: 4788–4795.

  • Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF . (2003). Ann NY Acad Sci 983: 84–100.

  • Turner BM . (2002). Cell 111: 285–291.

  • West RB, Yaneva M, Lieber MR . (1998). Mol Cell Biol 18: 5908–5920.

  • Wilson TE, Grawunder U, Lieber MR . (1997). Nature 388: 495–498.

  • Yoshida M, Kijima M, Akita M, Beppu T . (1990). J Biol Chem 265: 17174–17179.

  • Yoshida M, Matsuyama A, Komatsu Y, Nishino N . (2003). Curr Med Chem 10: 2351–2358.

  • Zgheib O, Huyen Y, DiTullio Jr RA, Snyder A, Venere M, Stavridi ES et al. (2005). Radiother Oncol 76: 119–122.

  • Zhang Y, Adachi M, Zhao X, Kawamura R, Imai K . (2004a). Int J Cancer 110: 301–308.

  • Zhang Y, Jung M, Dritschilo A, Jung M . (2004b). Radiat Res 161: 667–674.

  • Zhang Y, Reinberg D . (2001). Genes Dev 15: 2343–2360.

Download references

Acknowledgements

The support of the Australian Institute of Nuclear Science and Engineering is acknowledged. TCK was the recipient of AINSE awards. Molecular Radiation Biology and Epigenetics in Human Health and Disease Laboratories are supported by the National Health and Medical Research Council of Australia (350359 and 268905). Dr El-Osta acknowledges the Conquer Fragile X Foundation, Lyonel and Joanna Middows Foundation and the Hazel & Pip Appel Charitable Trust.

Author information

Authors and Affiliations

  1. Molecular Radiation Biology, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia

    T C Karagiannis

  2. Epigenetics in Human Health and Disease, Baker Medical Research Institute, The Alfred Medical Research and Education Precinct, Prahran, Vic, Australia

    A El-Osta

Authors
  1. T C Karagiannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A El-Osta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A El-Osta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karagiannis, T., El-Osta, A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25, 3885–3893 (2006). https://doi.org/10.1038/sj.onc.1209417

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209417

Keywords

This article is cited by

Search

Advanced search

Quick links